TRCT
IRWD icon

Tower Research Capital (TRC)’s Ironwood Pharmaceuticals IRWD Stock Holding History

Tower Research Capital (TRC)’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40K Sell
11,406
-3,743
-25% -$15.3K ﹤0.01% 2946
2025
Q4 		$51.1K Buy
15,149
+5,625
+59% +$14.6K ﹤0.01% 2399
2025
Q3 		$12.5K Sell
9,524
-18,478
-66% -$19.1K ﹤0.01% 3777
2025
Q2 		$20.1K Buy
28,002
+20,253
+261% +$15.9K ﹤0.01% 3677
2025
Q1 		$11.4K Sell
7,749
-9,772
-56% -$23.3K ﹤0.01% 3540
2024
Q4 		$77.6K Buy
17,521
+16,097
+1,130% +$65.3K ﹤0.01% 2305
2024
Q3 		$5.87K Sell
1,424
-28,552
-95% -$153K ﹤0.01% 4206
2024
Q2 		$195K Buy
29,976
+28,736
+2,317% +$203K ﹤0.01% 2093
2024
Q1 		$10.8K Sell
1,240
-4,142
-77% -$50.3K ﹤0.01% 3647
2023
Q4 		$61.6K Sell
5,382
-19,987
-79% -$198K ﹤0.01% 2991
2023
Q3 		$244K Buy
25,369
+11,181
+79% +$110K 0.01% 1308
2023
Q2 		$151K Buy
14,188
+6,506
+85% +$69.9K 0.01% 1749
2023
Q1 		$81K Sell
7,682
-7,752
-50% -$86.8K ﹤0.01% 2061
2022
Q4 		$191K Sell
15,434
-7,897
-34% -$89.6K 0.01% 1331
2022
Q3 		$242K Sell
23,331
-2,674
-10% -$30.3K ﹤0.01% 1731
2022
Q2 		$300K Buy
26,005
+17,772
+216% +$209K 0.01% 1481
2022
Q1 		$104K Sell
8,233
-19,868
-71% -$228K ﹤0.01% 2170
2021
Q4 		$328K Buy
28,101
+3,798
+16% +$46.6K 0.01% 1414
2021
Q3 		$317K Buy
24,303
+15,031
+162% +$194K 0.01% 1344
2021
Q2 		$119K Sell
9,272
-12,226
-57% -$140K ﹤0.01% 2289
2021
Q1 		$240K Buy
21,498
+15,858
+281% +$168K ﹤0.01% 1860
2020
Q4 		$64K Sell
5,640
-54,823
-91% -$600K ﹤0.01% 2844
2020
Q3 		$544K Buy
60,463
+22,237
+58% +$221K 0.01% 1590
2020
Q2 		$394K Buy
+38,226
New +$391K 0.02% 1218
2020
Q1 		– Sell
-16,350
Closed -$218K – 3469
2019
Q4 		$218K Buy
+16,350
New +$180K 0.02% 552
2019
Q3 		– Sell
-185
Closed -$2K – 4297
2019
Q2 		$2K Buy
+185
New +$2.07K ﹤0.01% 3274
2018
Q1 		– Sell
-596
Closed -$7K – 3543
2017
Q4 		$7K Sell
596
-17,093
-97% -$223K ﹤0.01% 2744
2017
Q3 		$234K Buy
+17,689
New +$243K 0.02% 652
2017
Q2 		– Sell
-13
Closed – – 3060
2017
Q1 		$0 Sell
13
-3,550
-100% -$48.5K ﹤0.01% 3474
2016
Q4 		$46K Buy
3,563
+902
+34% +$11.4K 0.01% 1483
2016
Q3 		$35K Sell
2,661
-1,735
-39% -$20.3K ﹤0.01% 1325
2016
Q2 		$48K Buy
4,396
+3,766
+598% +$36.8K ﹤0.01% 1581
2016
Q1 		$6K Buy
630
+480
+320% +$3.96K ﹤0.01% 2526
2015
Q4 		$1K Sell
150
-340
-69% -$3.29K ﹤0.01% 4095
2015
Q3 		$4K Sell
490
-725
-60% -$6.76K ﹤0.01% 2934
2015
Q2 		$12K Sell
1,215
-6,003
-83% -$69.8K ﹤0.01% 2533
2015
Q1 		$97K Buy
7,218
+6,272
+663% +$82.3K 0.01% 919
2014
Q4 		$12K Buy
946
+945
+94,500% +$10.8K ﹤0.01% 1986
2014
Q3 		$0 Sell
1
-1,049
-100% -$12K ﹤0.01% 4639
2014
Q2 		$14K Buy
1,050
+871
+487% +$9.47K ﹤0.01% 2095
2014
Q1 		$2K Sell
179
-60
-25% -$675 ﹤0.01% 3866
2013
Q4 		$2K Buy
239
+52
+28% +$467 ﹤0.01% 4013
2013
Q3 		$2K Sell
187
-4,257
-96% -$41.8K ﹤0.01% 4113
2013
Q2 		$37K Buy
+4,444
New +$53.9K ﹤0.01% 1167

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s IRWD Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Ironwood Pharmaceuticals (IRWD) stake by 25% in Q1 2026, selling an estimated $15.3K and leaving 11,406 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #2946.

Tower Research Capital (TRC) first reported a position in IRWD in Q2 2013 and has held it in 44 quarters since. The position peaked at $544K in Q3 2020. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Tower Research Capital (TRC) held 11,406 shares of Ironwood Pharmaceuticals worth $40K as of Q1 2026.
  • Tower Research Capital (TRC) sold 3,743 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $15.3K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2946 holding.
  • Tower Research Capital (TRC) first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Tower Research Capital (TRC)'s Ironwood Pharmaceuticals position peaked at $544K in Q3 2020.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.